These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Filella X, Foj L. Int J Mol Sci; 2016 Oct 26; 17(11):. PubMed ID: 27792187 [Abstract] [Full Text] [Related]
3. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F. Clin Chem; 2013 Jan 26; 59(1):280-8. PubMed ID: 23213079 [Abstract] [Full Text] [Related]
4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM. Eur Urol; 2016 Jul 26; 70(1):45-53. PubMed ID: 25985884 [Abstract] [Full Text] [Related]
11. Prostate-specific antigen and other serum and urine markers in prostate cancer. Stephan C, Ralla B, Jung K. Biochim Biophys Acta; 2014 Aug 26; 1846(1):99-112. PubMed ID: 24727384 [Abstract] [Full Text] [Related]
12. Current biomarkers for diagnosing of prostate cancer. Stephan C, Jung K, Ralla B. Future Oncol; 2015 Aug 26; 11(20):2743-55. PubMed ID: 26358139 [Abstract] [Full Text] [Related]
14. Emerging biomarkers in the detection and prognosis of prostate cancer. Filella X, Foj L. Clin Chem Lab Med; 2015 Jun 26; 53(7):963-73. PubMed ID: 25581761 [Abstract] [Full Text] [Related]
16. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects. Schmid M, Hansen J, Chun FK. Adv Exp Med Biol; 2015 Jun 26; 867():277-89. PubMed ID: 26530372 [Abstract] [Full Text] [Related]